期刊文献+

藏药余甘子抗肿瘤作用研究进展 被引量:20

A Research Progress on the Anti-Tumor Effects of Components in Phyllanthus Emblica L.
暂未订购
导出
摘要 余甘子为一种常用藏药,具有良好的抗肿瘤活性,在多个国家的传统民族药中作为抗癌药物使用。余甘子含有多种抗癌活性成分,其水提物抗癌活性极为明显,本文对余甘子中单体成分及提取物的抗癌药理作用及作用机制进行综述,为余甘子抗肿瘤药物研究和开发提供参考。 Phyllanthus emblica L.is related to traditional tibetan medicine,containing diversified pharmacological and physiological functions,such as anti-tumor effects,anti-inflammatory effects,anti-oxidation funtions,slow down in glycemia and blood pressure and the prevention of cardio-cerebral vascular diseases,etc.In this study,the research progress on the anti-tumor efficacy of monomer compounds and the extraction of Phyllanthus emblica L.were reviewed,providing references for the anti-tumor studies of Phyllanthus emblica L.
出处 《世界科学技术-中医药现代化》 2016年第7期1177-1181,共5页 Modernization of Traditional Chinese Medicine and Materia Medica-World Science and Technology
基金 国家自然科学基金委面上项目(81274187):基于藏药余甘子酚酸类成分体内动态变化的的抗癌药效物质与质量控制 负责人:张兰珍 北京市教育委员会科技成果转化与产业化项目 北京中医药大学科研创新团队(2011-CXTD-12) 负责人:石任兵
关键词 藏药 余甘子 抗肿瘤 作用机制 Tibetan medicine Phyllanthus emblica L. anti-tumor research progress
  • 相关文献

参考文献8

二级参考文献80

  • 1李国忠,郑咏秋.消风散颗粒免疫调节作用机理研究[J].中国实验方剂学杂志,2004,10(4):39-42. 被引量:19
  • 2吴雪辉,谢治芳,黄永芳.余甘子的化学成分和保健功能作用[J].中国野生植物资源,2003,22(6):69-71. 被引量:63
  • 3王宇翎,张艳,方明,李前进,江勤,明亮.白花蛇舌草总黄酮的免疫调节作用[J].中国药理学通报,2005,21(4):444-447. 被引量:143
  • 4[21]Chou TC,Talalay P.Analysis of combined drug effects:a new look at a very old problem.Trends Pharmacol Sci 1983;4:450-454
  • 5[22]Chou TC,Motzer RJ,Tong Y,Bosl GJ.Computerized quantitation of synergism and antagonism of taxol,topotecan,and cisplatin against human teratocarcinoma cell growth:a rational approachto clinical protocol design.J Natl Cancer Inst 1994;86:1517-1524
  • 6[23]Chen ST,Pan TL,Tsai YC,Huang CM.Proteomics reveals protein profile changes In doxorubicin-treated MCF-7 human breast cancer cells.Cancer Lett 2002;181:95-107
  • 7[24]Gandara DR,Perez EA,Weibe V,De Gregorio MW.Cisplatin chemoprotection and rescue:pharmacologic modulation of toxicity.Semin Oncol 1991;18:49-55
  • 8[25]Raghavan D,Koczwara B,Javle M.Evolving strategies of cytotoxic chemotherapy for advanced prostate cancer.Eur J Cancer 1997;33:566-574
  • 9[26]Von Hoff DD,Layard MW,Basa P,Davis HL Jr,Von Hoff AL,Rozencweig M,Muggia FM.Risk factors for doxorubicininduced congestive heart failure.Ann Intern Med 1979;91:710-717
  • 10[27]Hortobagyi GN.Progress in systemic chemotherapy of primary breast cancer:an overview.J Natl Cancer Inst Manogr 2001;72-79

共引文献118

同被引文献348

引证文献20

二级引证文献139

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部